Over the course of last few decades, the name “nonalcoholic fatty liver disease (NAFLD)" has faced severe criticism from numerous experts. This is because the term “non-alcoholic" in NAFLD plays a prominent role in the definition of NAFLD while underscoring the role of metabolic disease as the underlying pathophysiologic mechanism. It is well known to be associated with various components of metabolic syndrome such as, obesity and type 2 diabetes mellitus (T2DM). In fact, many experts consider NAFLD to be the hepatic manifestation of metabolic syndrome. The negative nomenclature has led to trivialization of NAFLD as a health condition in the past which might have resulted in it becoming a global pandemic. Hence a change in nomenclature from NAFLD to metabolic associated fatty liver disease or 'MAFLD' is welcoming. This change in nomenclature would bring this disease close to its pathophysiology and would also promote research, enhance clinician's understanding, and improve clinical care of the patients.